

ASTRAZENECA AND OUR YEAR IN BRIEF

ASTRAZENECA IS ONE OF THE WORLD'S LEADING PHARMACEUTICAL COMPANIES WITH A BROAD RANGE OF MEDICINES DESIGNED TO FIGHT DISEASE IN IMPORTANT AREAS OF HEALTHCARE. BACKED BY STRONG SCIENCE AND WIDE-RANGING COMMERCIAL SKILLS, WE ARE COMMITTED TO SUSTAINABLE DEVELOPMENT OF OUR BUSINESS AND THE DELIVERY OF A FLOW OF NEW MEDICINES THAT BRING BENEFIT FOR PATIENTS AND CREATE ENDURING VALUE FOR OUR SHAREHOLDERS AND SOCIETY.

2007 IN BRIEF

- > Sales up 7% to \$29,559 million.
- > *Crestor* sales up 33% to \$2,796 million;
Symbicort up 22% to \$1,575 million;
Seroquel up 15% to \$4,027 million;
and *Arimidex* up 10% to \$1,730 million.
Nexium sales down 2% to \$5,216 million.
- > Our product portfolio now includes 11 medicines with annual sales of more than \$1 billion each.
- > Sales up 17% in emerging markets.
- > Operating profit (excluding restructuring and synergy costs) up 8% to \$9,060 million.
- > Cash distributions to shareholders totalled \$6,811 million (dividends \$2,641 million; share re-purchases \$4,170 million).
- > Earnings per share (excluding restructuring and synergy costs) were \$4.20, ahead of target.
- > Dividend up 9% to \$1.87 for the full year.
- > Investment in R&D increased to more than \$5 billion.
- > A record 36 new compounds were selected for development and 24 compounds progressed to first human exposure. Phase III development pipeline doubled from five to 10 projects.
- > Over 20 major externalisation deals and two significant acquisitions in the past two years.
- > Acquisition of MedImmune in June 2007 established us as a leader in biotechnology amongst our pharmaceutical peers.
- > Productivity initiatives, including restructuring programme, progressing to plan.

FINANCIAL HIGHLIGHTS

Growth rates represent underlying performance, which shows growth at constant exchange rates (CER) by excluding the effects of exchange rate movements. Underlying CER growth is calculated by retranslating the current year's performance at the previous year's exchange rates and adjusting for other exchange effects, including hedging.

SALES \$M		
		GROWTH
07	29,559	+7%
06	26,475	+11%
05	23,950	+10%

OPERATING PROFIT \$M		
		GROWTH
07 ¹	9,060	+8%
07	8,094	-4%
06	8,216	+28%
05	6,502	+39%

PROFIT BEFORE TAX \$M		
		GROWTH
07 ¹	8,949	+2%
07	7,983	-9%
06	8,543	+29%
05	6,667	+41%

EARNINGS PER ORDINARY SHARE \$		
		GROWTH
07 ¹	4.20	+7%
07	3.74	-5%
06	3.86	+34%
05	2.91	+41%

R&D INVESTMENT \$M		
		GROWTH
07 ¹	5,089	+22%
07	5,162	+24%
06	3,902	+16%
05	3,379	-4%

SG&A COSTS \$M		
		GROWTH
07 ¹	9,886	+4%
07	10,364	+9%
06	9,096	+5%
05	8,695	+4%

RETURNS TO SHAREHOLDERS – DIVIDENDS AND SHARE RE-PURCHASES \$M		
07	6,811	
06	6,367	
05	4,718	

¹ Excluding restructuring and synergy costs.

PRODUCT PERFORMANCE SUMMARY \$M

NEXIUM -2%

07	5,216
06	5,182
05	4,633

SEROQUEL +15%

07	4,027
06	3,416
05	2,761

CRESTOR +33%

07	2,796
06	2,028
05	1,268

ARIMIDEX +10%

07	1,730
06	1,508
05	1,181

SYMBICORT +22%

07	1,575
06	1,184
05	1,006

PULMICORT +10%

07	1,454
06	1,292
05	1,162

SELOKEN/TOPROL-XL -22%

07	1,438
06	1,795
05	1,735

CASODEX +6%

07	1,335
06	1,206
05	1,123

ATACAND +9%

07	1,287
06	1,110
05	974

LOSEC/PRILOSEC -20%

07	1,143
06	1,371
05	1,652

ZOLADEX +4%

07	1,104
06	1,008
05	1,004

MERREM +20%

07	773
06	604
05	505

SYNAGIS¹

07	618
----	-----

FLUMIST¹

07	53
----	----

¹ Sales of MedImmune products are consolidated in AstraZeneca accounts from 1 June 2007. As a result, there are no prior period sales included.

DIVIDEND FOR 2007

	\$	Pence	SEK	Payment date
First interim dividend	0.52	25.3	3.49	17 September 2007
Second interim dividend	1.35	67.7	8.61	17 March 2008
Total	1.87	93.0	12.10	